Coripharma

www.coripharma.is

Reykjavikurvegur 78 - 80
Hafnarfjordur
220
Iceland

+354 420 6700

Activities

Summary

Coripharma is a European generic pharmaceutical company, built on solid heritage. The company’s experienced team offers contract manufacturing and out-licensing services to pharmaceutical companies that demand the highest quality and service from a reliable European supplier

Profile

Located in Iceland, inside Schengen and the European Economic Area (EEA), Coripharma’s manufacturing site was initially established in 1981 for local pharmaceutical production. In 1998 the facility was expanded with a 7,000 m2 factory and 900 m2 finished goods warehouse. With regular launches on day one, often as the first company to market after patents expired in Europe, the manufacturing site played an essential role in the growth story of Actavis.

CONTRACT MANUFACTURING

Coripharma specializes in pharmaceutical contract manufacturing; solid oral dosage forms, conventional and controlled generic pharmaceutical products.

Coripharma offers its clients:

  • Production
  • Packaging
  • Testing and EU releasing
  • Co-development

The company’s manufacturing site in Hafnarfjordur, Iceland, has an annual production capacity of about 1.2 billion tablets/capsules.

Equipment

Coripharma’s manufacturing site is equipped with machinery for standard mixing, granulation, tableting, film-coating and packaging.

Two granulation suites equipped with high-shear mixers and fluidized bed drying equipment (300 and 600 L capacity), offering batch sizes of up to 2 million tablets.

  • Water based or ethanol-based granulation.
  • Bin blending (up to 900 L capacity) offering direct compression batches of up to 4 million tablets.
  • Milling, both Quadro Comils and FitzMills.
  • Two film-coaters, offering both water and ethanol-based film coating.
  • Four Fette tableting compressors.
  • Five blistering lines, offering blister packaging using all major blistering materials incl Al/Al, Al/PVC, Acklar. All lines attached with serialization.
  • One line for bottle filling (PP, HDPE). Attached with serialization.

Good Manufacturing Practice

Coripharma‘s manufacturing site, a zero-carbon footprint facility, holds a GMP license for the European Union (EU). The facilities have also been successfully inspected by authorities in other major markets.

OUT-LICENSING

Coripharma offers out-licensing and supply of generic pharmaceuticals, developed in house,  including analytical development, regulatory- and IP support to other pharmaceutical companies. 

The company’s focus is on solid oral dose products; IR, tablets & capsules and ER tablets (DR & PR). Coripharma is also capable of developing powder/granule sachets and effervescent products.

Coripharma has an established development process, ranging from formulation to dossier completion and submission.

CORIPHARMA’S STORY

The Hafnarfjordur, Iceland site was taken over by Teva Pharmaceuticals in 2016, as part of its global acquisition of Actavis’ generics business. A group of former Actavis/Teva employees and local investors acquired the site from Teva in 2018. A year later Coripharma also purchased the former Actavis R&D site, located at the same premises.

Since then, Coripharma has further strengthened its team of highly experienced and reputable industry experts and executives. The company now successfully offers out-licensing of its own developed products and contract manufacturing to pharmaceutical companies in markets around the world.